App aims to boost ozempic adherence in diabetes patients

NCT ID NCT06478550

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a smartphone app helps people with type 2 diabetes stick with their weekly Ozempic injections. 304 participants either used the app or received standard care. The study tracked how long they stayed on the medication and if they reached their target dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

"Laiko" General Hospital of Athens

Goudi/Athens, 11527, Greece
General Hospital Of Thessaloniki Papageorgiou

Thessaloniki, Nea Efkarpia, 56429, Greece
General Hospital of Thessaloniki 'G. Gennimatas

Thessaloniki, 54635, Greece
Geniko Nosokomeio Peiraia Tzaneio

Piraeus, 18536, Greece
Univ Gen Hospital Larisa

Larissa, 41110, Greece
University Hospital of Athens ATTIKON

Athens, Attica, 12462, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.